X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Vectura will support the development of a single use device/formulation combination for evaluation in Phase I of inhaled oxytocin, and then expedite technical transfer to a commercial manufacturer to advance to Phase III and commercial launch.
Lead Product(s): Oxytocin
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Monash University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 14, 2020
Chinaplas 2024
Not Confirmed
Contact SupplierDetails:
Emifarma will be responsible for the initial stages of development and testing of the Company’s Mango ED products, including Mango ED, a combination of Tadalafil, Oxytocin, and L-Arginine, intended for the Mexican and Latin American markets.
Lead Product(s): Tadalafil,Oxytocin,L-Arginine
Therapeutic Area: Psychiatry/Psychology Product Name: Mango ED
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mangoceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 12, 2024
Details:
The Company intends to use the net proceeds to finance the marketing and operational expenses associated with the planned marketing of its Mango ED, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction.
Lead Product(s): Tadalafil,Oxytocin,L-Arginine
Therapeutic Area: Psychiatry/Psychology Product Name: Mango ED
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boustead Securities
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 15, 2023
Details:
TNX-2900" (Oxytocin Magnesium) is an Oxytocin receptor Agonist Peptide drug candidate, which is currently being evaluated for the treatment of Prader-Willi syndrome.
Lead Product(s): Oxytocin,Magnesium
Therapeutic Area: Genetic Disease Product Name: TNX-2900
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
TNX-1900 (oxytocin) is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP.
Lead Product(s): Oxytocin
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-1900
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
TNX-1900 (oxytocin) is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP.
Lead Product(s): Oxytocin
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-1900
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
Mango (sildenafil citrate) mango-flavored, rapid dissolve tablet is a Phosphodiesterase-5 inhibitor, which is being indicated for the treatment of erectile dysfunction.
Lead Product(s): Sildenafil Citrate,Oxytocin,L-Arginine
Therapeutic Area: Psychiatry/Psychology Product Name: Mango
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
The partnership aims bring its flagship product, Mango, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction, to New York.
Lead Product(s): Tadalafil,Oxytocin,L-Arginine
Therapeutic Area: Psychiatry/Psychology Product Name: Mango
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Greater NY Chamber of Commerce
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 09, 2023
Details:
TNX-1900 (oxytocin) interrupts pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP, which is investigated for the treatment of Binge-Eating Disorder.
Lead Product(s): Oxytocin
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-1900
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
The agreement aims for the development of TNX-1900 (potentiated intranasal oxytocin) for enhancing social safety learning in social anxiety disorder (SAD).
Lead Product(s): Oxytocin
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-1900
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: University of Washington
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 17, 2023
Details:
Under the collaboration, Endo's Par Sterile Products business will supply Pitocin® (oxytocin injection, USP) vials through Premier's ProvideGx® and PremierProRx® programs. Pitocin® is used to induce labor in pregnant women.
Lead Product(s): Oxytocin
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Pitocin
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Premier
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 17, 2023
Details:
TNX-1900 (intranasal potentiated oxytocin) is a proprietary formulation of oxytocin in development as a candidate for prevention of pediatric obesity, chronic migraine and other conditions.
Lead Product(s): Oxytocin
Therapeutic Area: Nutrition and Weight Loss Product Name: TNX-1900
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
The research collaboration agreement aims to evaluate the effect of TNX-1900 (intranasal potentiated oxytocin) on capsaicin- or electrical stimulation-induced forehead dermal blood flow in healthy female human volunteers.
Lead Product(s): Oxytocin
Therapeutic Area: Neurology Product Name: TNX-1900
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Erasmus University Medical Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 22, 2023
Details:
TNX-2900 (oxytocin) is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP. It is being investigayed for prader-willi syndrome.
Lead Product(s): Oxytocin,Magnesium
Therapeutic Area: Genetic Disease Product Name: TNX-2900
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
TNX-1900 (oxytocin) interrupts pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP.
Lead Product(s): Oxytocin
Therapeutic Area: Neurology Product Name: TNX-1900
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
TNX-1900 (oxytocin) is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP.
Lead Product(s): Oxytocin
Therapeutic Area: Neurology Product Name: TNX-1900
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Details:
TNX-1900 (intranasal potentiated oxytocin) is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP.
Lead Product(s): Oxytocin,Magnesium
Therapeutic Area: Neurology Product Name: TNX-1900
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
Details:
TNX-1900 (intranasal potentiated oxytocin) is a proprietary formulation of oxytocin in development as a candidate for prophylaxis of chronic migraine and for the treatment of craniofacial pain, insulin resistance and related conditions.
Lead Product(s): Oxytocin
Therapeutic Area: Neurology Product Name: TNX-1900
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
TNX-2900, Tonix’s proprietary potentiated intranasal oxytocin is in the pre-Investigational New Drug (IND) stage as a candidate for the treatment of Prader-Willi syndrome (PWS) and non-organic failure to thrive disease.
Lead Product(s): Oxytocin,Magnesium
Therapeutic Area: Nutrition and Weight Loss Product Name: TNX-2900
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
Intranasal TNX-1900 (oxytocin) with magnesium demonstrated augmented craniofacial analgesia in an animal model enhanced effect of mg2+ is the core patented technology of TNX-1900 (oxytocin) for migraine.
Lead Product(s): Oxytocin,Magnesium
Therapeutic Area: Neurology Product Name: TNX-1900
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
TNX-1900 is also in development for the treatment of chronic migraine and is expected to enter a multi-site Phase 2 potential pivotal clinical trial for the prevention of migraine headache in chronic migraineurs in the second half of 2022.
Lead Product(s): Oxytocin
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-1900
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Harvard Medical School
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 07, 2022
Details:
U.S. FDA has granted Orphan-Drug Designation for TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome, underscores the urgent, unmet medical need for patients diagnosed with this disease.
Lead Product(s): Oxytocin
Therapeutic Area: Genetic Disease Product Name: TNX-2900
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
Details:
ICOone® delivers a dry powder, there is no need for expensive and complicated cold storage. Inhaling the drug eliminates the use of disposable syringes and no hazardous waste with blood contaminated syringes is generated.
Lead Product(s): Oxytocin
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ICOone
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
The new program at Tonix has the designation TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome.
Lead Product(s): Oxytocin
Therapeutic Area: Genetic Disease Product Name: TNX-2900
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 11, 2021
Details:
This license allows Tonix to expand its intranasal potentiated oxytocin development program, TNX-1900, into cardiometabolic syndromes, which include insulin resistance, impaired glucose tolerance, and obesity.
Lead Product(s): Oxytocin
Therapeutic Area: Endocrinology Product Name: TNX-1900
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 22, 2020
Details:
The agreement gives Monash an exclusive global right to use ICOone with oxytocin to prevent postpartum haemorrhage in women giving birth.
Lead Product(s): Oxytocin
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ICOone
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: Monash University
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 21, 2020
Details:
The data show that intranasal oxytocin, but not intravenous oxytocin or vehicle, attenuated both reactive and spontaneous pain following mild traumatic brain injury in an animal model.
Lead Product(s): Oxytocin
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-1900
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
Details:
Preclinical results of TNX-1900 (oxytocin solution for intranasal delivery) will be presented in a poster at the American Academy of Neurology’s first-ever Sports Concussion Conference.
Lead Product(s): Oxytocin
Therapeutic Area: Neurology Product Name: TNX-1900
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
Tonix will acquire the migraine and pain treatment technologies of Trigemina, Inc., and will assume the license for some of the technologies from Stanford University.
Lead Product(s): Oxytocin
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
